 The Global Alliance for Progress (GAP) in hemophilia is a 10-year healthcare development project, launched in April 2003. GAP’s goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.
The project aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with hemophilia, and the gap between the amount of treatment product needed versus what is available.
To-date, a total of 23,324 patients with hemophilia, 2,423 with von Willebrand disease (VWD) and 1,509 with rare clotting factor deficiencies have been diagnosed/registered through the GAP program.
GAP partners include Baxter, Bayer, Biotest, Biogen, CSL Behring, Pfizer, Grifols, the Jan Willem André de la Porte Family Foundation, the Irish Hemophilia Society, and the World Health Organization (WHO).
GAP country programs are designed to improve five main areas: government support, the care delivery system, medical expertise and diagnosis, quality and quantity of treatment products, and the national hemophilia organization.
 There are presently 11 ongoing GAP countries, including Belarus, Ecuador, Jordan, Lebanon, Moldova, Peru, South Africa, Thailand, Tunisia, China, and Syria. Previous GAP countries included Armenia, Azerbaijan, Egypt, Georgia, Mexico, the Philippines, and Russia.
GAP training, education, and information materials also reach out to the entire hemophilia community. Several other countries are accessing GAP information on the WFH web site to implement their own development projects, using the tools and model developed by the Federation.
Steps for Developing National Hemophilia Care Programs
GAP Program
Resources
For more information on GAP, contact Antonio Almeida at aalmeida@wfh.org.
Last Updated December 2011
|
